Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

Augmentation strategies for treatment-resistant depression.

Carvalho AF, Machado JR, Cavalcante JL.

Curr Opin Psychiatry. 2009 Jan;22(1):7-12. doi: 10.1097/YCO.0b013e32831be9ef. Review.

PMID:
19122528
2.

Augmentation strategies for treatment-resistant depression: a literature review.

Carvalho AF, Cavalcante JL, Castelo MS, Lima MC.

J Clin Pharm Ther. 2007 Oct;32(5):415-28. Review.

PMID:
17875106
3.

What role do atypical antipsychotic drugs have in treatment-resistant depression?

Thase ME.

J Clin Psychiatry. 2002 Feb;63(2):95-103. Review.

PMID:
11874227
4.

Augmentation and combination strategies in treatment-resistant depression.

Fava M.

J Clin Psychiatry. 2001;62 Suppl 18:4-11. Review.

5.

Augmentation of standard depression therapy.

Marangell LB.

Clin Ther. 2000;22 Suppl A:A25-38; discussion A39-41. Review.

PMID:
10815648
6.

[Augmentation strategies for therapy resistant depression - a review].

Schmauss M, Messer T.

Psychiatr Prax. 2007 May;34(4):165-74. Epub 2006 Dec 7. Review. German.

PMID:
17160747
7.

Therapeutic options for treatment-resistant depression.

Shelton RC, Osuntokun O, Heinloth AN, Corya SA.

CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000. Review.

PMID:
20088620
8.

Augmentation strategies in patients with refractory depression.

Nemeroff CB.

Depress Anxiety. 1996-1997;4(4):169-81. Review.

PMID:
9166649
9.

Potentiation strategies for treatment-resistant depression.

Ros S, Agüera L, de la Gándara J, Rojo JE, de Pedro JM.

Acta Psychiatr Scand Suppl. 2005;(428):14-24, 36. Review.

PMID:
16307616
10.

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.

Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T.

Can J Psychiatry. 2003 Aug;48(7):440-8. Review.

PMID:
12971013
11.

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.

Connolly KR, Thase ME.

Drugs. 2011 Jan 1;71(1):43-64. doi: 10.2165/11587620-000000000-00000. Review.

PMID:
21175239
12.

Update on augmentation of antidepressant response in resistant depression.

DeBattista C, Lembke A.

Curr Psychiatry Rep. 2005 Dec;7(6):435-40. Review.

PMID:
16318821
13.

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2009;70 Suppl 6:16-25. doi: 10.4088/JCP.8133su1c.03. Review.

14.

The use of antidepressants in novel combination therapies.

Shelton RC.

J Clin Psychiatry. 2003;64 Suppl 2:14-8. Review.

16.

Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.

Bschor T, Lewitzka U, Sasse J, Adli M, Köberle U, Bauer M.

Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S230-4. Review.

PMID:
14677084
17.

A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician.

Schweitzer I, Tuckwell V, Johnson G.

Aust N Z J Psychiatry. 1997 Jun;31(3):340-52. Review. Erratum in: Aust N Z J Psychiatry 1997 Oct;31(5):787.

PMID:
9226079
18.

Treatment of antidepressant nonresponders: augmentation or switch?

Nelson JC.

J Clin Psychiatry. 1998;59 Suppl 15:35-41. Review.

19.
20.

Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.

Chang CM, Sato S, Han C.

CNS Drugs. 2013 May;27 Suppl 1:S21-7. doi: 10.1007/s40263-012-0030-1. Review.

PMID:
23712796
Items per page

Supplemental Content

Write to the Help Desk